Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2017)
9 slides from Csl's shareholder meeting presentation, Oct 18, 2017
Slide 1: CSL Limited Annual General Meeting 2017
CSL LIMITED ANNUAL GENERAL MEETING 2017
Slide 2: Legal Notice
Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all o
Slide 3: Strategic Objectives
Strategic Objectives Growth Maximize portfolio value & deliver new product launches Efficiency Be the most efficient, highest quality plasma player Influenza Deliver on influenza strategy Pursue new opportunities to diversify portfolio Innovation and enhance growth Create a culture that attracts, re
Slide 4: Delivering on Strategy: Growth
Delivering on Strategy Growth • Global leader in immunoglobulins – Focused commercial execution • Innovation in haemophilia – IDELVION® new standard of care – AFSTYLA® new generation rFVIII • Exceptional growth in specialty products – HAEGARDA® approved • Ruide providing access to high growth China
Slide 5: Delivering on Strategy: Innovation and Efficiency
Delivering on Strategy Innovation Efficiency • 3 global launches in 15 months • 5 years of margin expansion • Largest ever CIDP clinical study completed • Most efficient plasma collection network • 3 new mAbs into phase 1 trials – Industry leading expansion • Collaboration to develop Fc mimetic • Tr
Slide 6: Delivering on Strategy: Influenza and People & Culture
Delivering on Strategy Influenza People & Culture • On-track to profitability • Workforce ~20,000 • Broad product portfolio driving strong • Maintaining and growing a values based sales growth culture • Shipping commenced of >50m doses to – Patient focus US – Geographic expansion • Four-fold increas
Slide 7: Revenue Highlights
Revenue Highlights IMMUNOGLOBULINS HAEMOPHILIA SPECIALTY ALBUMIN SEQIRUS $2,774m +14%1 $1,023m +4%1 $1,174m +20%1 $840m +7%1 $900m +23%1 • Privigen® up 21%1 • Strong demand for • Kcentra® up 35%1 • Expansion into • Fluad®, QIVs and IDELVION® additional cities TIV all contributing • Hizentra® up 10%1
Slide 8: Investing to Support Sales Growth
Investing to Support Sales Growth $M Capex $B Sales • Key projects 1,000 7 – Lengnau Sales 6 – Kankakee & Marburg: New base 800 fractionation capacity 5 – Marburg: Additional Haegarda® / Berinert® 600 4 capacity Capital – Broadmeadows: New albumin & Ig Expenditure 400 3 capacity – Bern: New Ig capac
Slide 9: Outlook
Outlook • FY18 NPAT1,2 ~$1,480m – $1,550m @ CC3 Reaffirmed • Investing in new plasma opportunities • Planning for CSL 112 (apoA-I) Phase III continuing • Transplant • Monoclonal antibodies • Expanding into the high growth China market • Majority stake in Ruide • Investing in new biotech opportunitie